IMRNW (Immuron) Other Gross PPE : $0.16 Mil (As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Immuron Other Gross PPE?

Immuron's Other Gross PPE for the quarter that ended in Jun. 2024 was $0.16 Mil.

Immuron's quarterly Other Gross PPE declined from Jun. 2023 ($0.16 Mil) to Dec. 2023 ($0.12 Mil) but then increased from Dec. 2023 ($0.12 Mil) to Jun. 2024 ($0.16 Mil).

Immuron's annual Other Gross PPE increased from Jun. 2022 ($0.16 Mil) to Jun. 2023 ($0.16 Mil) but then declined from Jun. 2023 ($0.16 Mil) to Jun. 2024 ($0.16 Mil).

Immuron Other Gross PPE Historical Data

The historical data trend for Immuron's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Other Gross PPE Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Other Gross PPE

Get a 7-Day Free Trial

0.05

0.03

0.16

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Gross PPE	Get a 7-Day Free Trial													0.16	0.14	0.16	0.12	0.16

Immuron Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Immuron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (NAS:IMRNW) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

IMRN:USA ANWA:Germany ANWA:Germany ANW:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.